| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 311.0 | 364.2 |
| Gross profit | 202.2 | 256.7 |
| Profit before tax | 1.9 | 16.0 |
| Net income | -0.7 | 17.1 |
| EPS (diluted, $ a share) | $-0.02 | $0.34 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -14.6% |
|---|---|
| Gross margin | 65.0% |
| Operating margin | 1.6% |
10-Q filed with the SEC, NYSE: NUS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nu Skin Enterprises, Inc.: key numbers
- Share price
- $3.93Close, Nov 16
- Market cap
- $191M
- Shares outstanding
- 48.68MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nu Skin Enterprises, Inc.
All →Nu Skin Enterprises Financial Results
Nu Skin Enterprises reported Q3 2026 revenue of $311.0 million, a 14.6% decrease year-over-year, which fell within its guidance range. The company reported a GAAP loss per share of $0.02 and adjusted EPS of $0.10, while providing Q4 revenue guidance of $310 million to $340 million.
- Term
- Q3 2026
“Third quarter revenue came in within our guidance range as we continued executing on our strategic priorities amid a challenging operating environment.”
Ryan Napierski, Nu Skin president and CEO
“For 2026, we project revenue of $1.26 billion to $1.29 billion and earnings per share of $(5.08) to $(4.98) with adjusted EPS of $0.55 to $0.65.”
Chelsea Lantz, interim chief financial officer